Skip to main content

Table 3 Factors associated with change in E/e′ from baseline to 24 months

From: Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study

  Model 1 Model 2 Model 3
N = 115, R = 0.26 N = 115, R = 0.27 N = 115, R = 0.55
β p value β p value β p value
Sitagliptin −8.910 0.006 −8.887 0.007 −9.959 0.001
E/e′ −0.094 0.889 −0.159 0.820 −0.240 0.716
Male gender    0.674 0.845 0.149 0.966
Age    0.330 0.392 −0.005 0.990
Systolic blood pressure      −0.293 0.095
HbA1c      6.614 0.272
Cardiovascular disease      −5.631 0.142
Chronic heart failure      10.819 0.070
α-glucosidase inhibitor      1.053 0.734
Biguanide      −14.839 0.001
Glinide      −10.778 0.072
Sulfonylurea      −0.567 0.891
Thiazolidinedione      2.159 0.572
LV ejection fraction      0.178 0.602
LV mass index      0.348 <0.001
  1. Model 1 means ANCOVA adjusted for baseline E/e′. Model 2 were adjusted for Model 1 and sex, age. Model 3 were adjusted for Model 2 and systolic blood pressure, HbA1c, cardiovascular disease, chronic heart failure, α-glucosidase inhibitor, bigunaide, glinide, sulfonylurea, thiazolidinedione, LV ejection fraction, LV mass index, whose data were obtained at baseline examination
  2. Abbreviations, see Tables 1 and 2